What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Frame 427318887.png
ENTRESTO - Page 5 img1 1.png

Abbreviations

†Paragon-HF defined HFpEF as patients with LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. Paraglide-HF defined HFmrEF and HFpEF as patients with LVEF > 40%. LVEF is a variable measure, and the normal range can vary.6

ENTRESTO® NSS -  UAE

PDF
View

References

  1. ENTRESTO [prescribing information]. Novartis Pharmaceutical Corporation East Hanover, NJ; April 2024

 

  1. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;S0735-1097(23):05429-3. doi:10.1016/j.jacc.2023.04.019